Pr Alexander M. Eggermont of Institut Gustav Roussy in Paris and study coordinator of EORTC trial 18071, presented the initial efficacy and safety results from that phase III trial at ASCO 2014 in Chicago. This trial showed that adjuvant therapy with ipilimumab (Yervoy) for patients with high-risk stage III melanoma significantly improved recurrence-free survival. An overview of the trial results were reported 06 June 2014 in The ASCO Post.
Pr Alexander Eggermont presented the initial efficacy and safety results from EORTC trial 18071 at ASCO 2014 in Chicago
Methodologies for conducting trials and other studies, including data handling and analysis at ESTRO-EORTC wor... 26/04/2017
27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) – EORTC session: Infections... 06/04/2017